Form D · Pharmaceuticals

Biodexa Pharmaceuticals Plc

Cardiff, X0 · CIK 0001643918

Offering snapshot reported Aug 1, 2024 · SEC filing

Reported sold
$5.01M
Offering amount: $5.01M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 19, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 1, 2024Initial$5,009,968No comparison7SEC filing
Jan 4, 2024Initial$6,793,406No comparison1SEC filing
Jun 7, 2023Initial$3,320,388No comparison15SEC filing
Feb 17, 2023Initial$5,999,223No comparison6SEC filing
Jun 4, 2020Initial$3,000,000No comparison7SEC filing
Nov 7, 2019Initial$3,000,000No comparison1SEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$401K
Finders' fees
$0
Form D file number
021-520379

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Ladenburg Thalmann & Co. Inc.505

Source: Form D, filed Aug 1, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Craig Cook Director, Executive
Sijmen De Vries Director
Frederic Duchesne Director
Ann Merchant Executive
Stephen Parker Director
Huaizheng Peng Director
Rolf Stahel Director
Stephen Stamp Director, Executive
Simon Turton Director
Dmitry Zamoryakhin Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1 Caspian Point Caspian Way
Cardiff, X0, CF10 4DQ